The gene-regulatory networks enriched by CRP/IL6 pathways revealed in a tissue-specific manner a number of key driver genes, of which both well-established (e.g., JAK1/2/3 and STAT3) and novel (e.g., CXCR3, CD3D, CD3G, and STAT6) drug targets were recognized for their shared mechanisms in regulating CRP/IL6 and BC risk. This evidence concerns the gene JAK1 and breast cancer.